On December 5, 2023, Renee Tannenbaum, a director of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), executed a transaction involving the sale of 1,800 shares of the company’s stock. The shares were sold at an average price of $81.15, resulting in a total transaction value of $146,070. Following this sale, Tannenbaum’s remaining holdings in ANI Pharmaceuticals consist of 25,157 shares, which are valued at approximately $2,041,490.55. This sale represents a 6.68% reduction in her overall position in the company.
Market Performance and Financial Overview
As of Wednesday, ANI Pharmaceuticals shares opened at $81.67. The company has a market capitalization of $1.84 billion and a price-to-earnings (P/E) ratio of 50.10. The stock has demonstrated relatively low volatility with a beta of 0.48. Over the past year, ANI Pharmaceuticals has seen its share price fluctuate between a twelve-month low of $52.50 and a high of $99.50. The firm’s 50-day and 200-day simple moving averages are $88.09 and $80.36, respectively.
Recently, ANI Pharmaceuticals reported its quarterly earnings on November 7, 2023. The specialty pharmaceutical company achieved earnings per share (EPS) of $2.04, exceeding analysts’ consensus estimates of $1.74 by $0.30. The firm also reported revenues of $227.81 million for the quarter, surpassing expectations of $211.92 million. This reflects a significant year-over-year revenue increase of 53.6% compared to the same period last year when the company recorded an EPS of $1.34.
Looking ahead, ANI Pharmaceuticals has set its fiscal year 2025 guidance at 7.370-7.640 EPS. Analysts forecast that the company will post an EPS of 3.86 for the current fiscal year.
Institutional Investors and Shareholder Activity
In recent months, several institutional investors have adjusted their stakes in ANI Pharmaceuticals. Notably, Hantz Financial Services Inc. increased its stake by 202.6% during the third quarter, now holding 354 shares valued at approximately $32,000. Additionally, Advisors Asset Management Inc. acquired a new stake in the company worth around $28,000 in the first quarter.
Furthermore, Caitong International Asset Management Co. Ltd raised its position in ANI Pharmaceuticals by an impressive 4,636.4% in the second quarter, now owning 521 shares valued at $34,000. Similarly, Newbridge Financial Services Group Inc. increased its holdings by 200.0%, totaling 600 shares worth $39,000.
Currently, institutional investors hold approximately 76.05% of ANI Pharmaceuticals’ stock, indicating strong confidence in the company’s future performance.
Founded in the United States, ANI Pharmaceuticals develops, manufactures, and markets both branded and generic prescription pharmaceuticals throughout North America. The company specializes in a variety of product forms, including oral solid doses, semi-solids, liquids, and topicals, alongside contract development and manufacturing services.
As the market continues to evolve, the activities of directors and institutional investors will remain closely monitored, reflecting broader trends in investor confidence and stock performance.
